May 12, 2025 10:34 AM EDTUpdated 12:41 PM
News Briefing

FDA clears in vi­vo blood stem cell edit­ing tri­al; Abeon­a's $155M PRV sale

ENDPOINTS

Plus, news about Cy­tomX, Val­ne­va, Lenz and Lo­tus Phar­ma­ceu­ti­cal:

🧪 Af­ter Chi­na, US green­lights first tri­al of in vi­vo blood stem …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

TRENDING NOW

Up­dat­ed: White House threat­ens ‘most fa­vored na­tion’ plan to low­er US drug prices, but many ques­tions re­main

Lack of de­tail in Trump's drug price plan rais­es more ques­tions than an­swers

Phar­ma in­vestors brush off Trump’s ‘most fa­vored na­tion’ plan as stocks rise

Ex­clu­sive: Patrick Hsu start­up launch­es, looks be­yond CRISPR for gene in­ser­tion tech­nol­o­gy

Roche could re­think $50B US ex­pan­sion plan if new poli­cies 'har­m' op­er­a­tions

Vir’s hep B dis­ap­point­ment, Ipsen's new Iqir­vo da­ta, plus more from #EASL25

A service from the Financial Times